NBTX 4.73 Nanobiotix S.A.
| Range: | 4.14-8.962 | Vol Avg: | 9343 | Last Div: | 0 | Changes: | -0.23 |
| Beta: | 1.29 | Cap: | 0.22B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Dec 11 2020 | Empoloyees: | 110 | ||
| CUSIP: | 63009J107 | CIK: | 0001760854 | ISIN: | US63009J1079 | Country: | FR |
| CEO: | Mr. Laurent Levy Ph.D. | Website: | https://www.nanobiotix.com | ||||
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Stock Details
NBTX 12
Nanobiotix initiated with a Buy at Guggenheim
Michael Schmidt·Tue Aug 27 2024
Guggenheim
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow